Publication date: Jan 14, 2026
Remote, internet-based deep brain stimulation programming for Parkinson’s disease accelerates clinical benefits postoperatively by improving access to therapy adjustments compared to in-clinic optimization. After completion of the initial digital programming phase, we show that clinical outcomes, quality of life, and safety remain sustained over at least twelve months under routine care conditions. Embedding a randomized trial within a larger cohort study enables long-term, real-world evaluation, offering a scalable and pragmatic model for assessing complex digital interventions in routine clinical care. (NCT05269862 registered on 2022-03-08 and NCT04071847 registered on 2019-08-28).
Open Access PDF
| Concepts | Keywords |
|---|---|
| Accelerates | Assessment |
| Clinic | Brain |
| Nct05269862 | Care |
| Parkinson | Clinical |
| Deep | |
| Digital | |
| Multicenter | |
| Outcomes | |
| Programming | |
| Real | |
| Registered | |
| Routine | |
| Stimulation | |
| Sustained | |
| World |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Parkinson’s disease |
| drug | DRUGBANK | Sulfasalazine |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| disease | MESH | Movement Disorder |
| disease | MESH | Neurodegenerative Diseases |
| pathway | REACTOME | Neurodegenerative Diseases |
| disease | MESH | DBS |
| disease | MESH | MDS |
| drug | DRUGBANK | Levodopa |
| disease | MESH | emergency |
| disease | MESH | death |
| drug | DRUGBANK | Isoxaflutole |
| disease | MESH | CND |
| disease | MESH | Dis |
| disease | MESH | Parkinsonism |
| pathway | KEGG | Parkinson disease |
| disease | MESH | COVID 19 |
| disease | MESH | face |
Original Article
(Visited 56 times, 1 visits today)